Hiroyu Hatano

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells
    Hiroyu Hatano
    Department of Medicine, San Francisco General Hospital, 995 Potrero Ave, San Francisco, CA 94110, USA
    J Infect Dis 208:50-6. 2013
  2. pmc Immune activation and HIV persistence: considerations for novel therapeutic interventions
    Hiroyu Hatano
    Department of Medicine, University of California San Francisco, San Francisco, California 94110, USA
    Curr Opin HIV AIDS 8:211-6. 2013
  3. pmc A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection
    Hiroyu Hatano
    Department of Medicine, University of California, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 61:317-25. 2012
  4. pmc A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response
    Hiroyu Hatano
    University of California, San Francisco, USA
    J Infect Dis 203:960-8. 2011
  5. pmc Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals
    Hiroyu Hatano
    Department of Medicine, University of California, San Francisco, California, USA
    AIDS 24:2535-9. 2010
  6. pmc Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy
    Hiroyu Hatano
    University of California, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 54:389-93. 2010
  7. pmc Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy
    Hiroyu Hatano
    San Francisco General Hospital, Building 80, Ward 84, 995 Potrero Avenue, San Francisco, CA 94110, USA
    J Virol 83:329-35. 2009
  8. pmc A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers
    Peter W Hunt
    Departments of Medicine and Laboratory Medicine, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 6:e15924. 2011
  9. pmc Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients
    Priscilla Y Hsue
    Division of Cardiology, Positive Health Program of the Department of Medicine, San Francisco General Hospital, University of California San Francisco, 1001 Potrero Avenue, San Francisco, CA 94110, USA
    AIDS 23:2021-7. 2009
  10. pmc HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers
    Peter W Hunt
    Department of Medicine, University of California, San Francisco, California, USA
    Clin Infect Dis 52:681-7. 2011

Detail Information

Publications21

  1. pmc Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells
    Hiroyu Hatano
    Department of Medicine, San Francisco General Hospital, 995 Potrero Ave, San Francisco, CA 94110, USA
    J Infect Dis 208:50-6. 2013
    ..Studies aimed at defining the association between host immune responses and human immunodeficiency virus (HIV) persistence during therapy are necessary to develop new strategies for cure...
  2. pmc Immune activation and HIV persistence: considerations for novel therapeutic interventions
    Hiroyu Hatano
    Department of Medicine, University of California San Francisco, San Francisco, California 94110, USA
    Curr Opin HIV AIDS 8:211-6. 2013
    ....
  3. pmc A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection
    Hiroyu Hatano
    Department of Medicine, University of California, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 61:317-25. 2012
    ..To determine whether intensification with raltegravir improves endothelial function in antiretroviral-treated HIV-infected individuals...
  4. pmc A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response
    Hiroyu Hatano
    University of California, San Francisco, USA
    J Infect Dis 203:960-8. 2011
    ..We conducted an intensification study to assess whether residual viral replication contributes to replenishment of the latent reservoir and whether mucosal HIV-specific T cell responses limit the reservoir size...
  5. pmc Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals
    Hiroyu Hatano
    Department of Medicine, University of California, San Francisco, California, USA
    AIDS 24:2535-9. 2010
    ..HAART can effectively reduce plasma HIV RNA levels to below the level of detection in most HIV-infected patients. The degree to which residual low-level viremia persists during HAART remains unclear...
  6. pmc Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy
    Hiroyu Hatano
    University of California, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 54:389-93. 2010
    ..Although integrase inhibitors are highly effective in the management of drug-resistant HIV, some patients fail to achieve durable viral suppression. The long-term consequences of integrase inhibitor failure have not been well defined...
  7. pmc Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy
    Hiroyu Hatano
    San Francisco General Hospital, Building 80, Ward 84, 995 Potrero Avenue, San Francisco, CA 94110, USA
    J Virol 83:329-35. 2009
    ..This confirms the failure to eradicate the virus, even in these unique individuals who are able to reduce plasma viremia to very low levels without antiretroviral therapy...
  8. pmc A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers
    Peter W Hunt
    Departments of Medicine and Laboratory Medicine, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 6:e15924. 2011
    ..These data support a model in which low frequencies of Tregs in HIV controllers may contribute to an effective adaptive immune response, but may also contribute to generalized immune activation, potentially contributing to CD4 depletion...
  9. pmc Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients
    Priscilla Y Hsue
    Division of Cardiology, Positive Health Program of the Department of Medicine, San Francisco General Hospital, University of California San Francisco, 1001 Potrero Avenue, San Francisco, CA 94110, USA
    AIDS 23:2021-7. 2009
    ..As endothelial dysfunction is central to the pathogenesis of atherosclerosis, we tested the hypothesis that current treatment with abacavir is associated with impaired endothelial function...
  10. pmc HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers
    Peter W Hunt
    Department of Medicine, University of California, San Francisco, California, USA
    Clin Infect Dis 52:681-7. 2011
    ..Despite robust immune responses, these individuals never eradicate HIV infection. We hypothesized that HIV-specific CD4(+) T cells might serve as target cells for HIV, contributing to viral persistence in this setting...
  11. pmc Comparison of HIV DNA and RNA in gut-associated lymphoid tissue of HIV-infected controllers and noncontrollers
    Hiroyu Hatano
    aDepartment of Medicine bDepartment of Epidemiology and Biostatistics, University of California cSan Francisco Veterans Affairs Medical Center, San Francisco, California, USA
    AIDS 27:2255-60. 2013
    ..HIV-infected controllers have provided novel insights into mechanisms of viral control. We investigated the degree to which HIV DNA and RNA are present in gut-associated lymphoid tissue (GALT) of controllers...
  12. pmc Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers
    Hiroyu Hatano
    Department of Medicine, University of California San Francisco, San Francisco, California, United States of America
    PLoS Pathog 9:e1003691. 2013
    ..These data confirm that HIV replication persists in controllers and contributes to a chronic inflammatory state. ART should be considered for these individuals (ClinicalTrials.gov NCT01025427). ..
  13. pmc A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells
    Steven A Yukl
    aSan Francisco Veterans Affairs Medical Center bUniversity of California, San Francisco UCSF, California, USA
    AIDS 28:439-42. 2014
    ..HIV DNA levels in total rectal cells were greater than those predicted from levels in sorted CD4 T cells, suggesting a reservoir in non-CD4 T cells, and HIV DNA was detected in sorted myeloid cells (7/7 subjects)...
  14. pmc Impact of HIV on CD8+ T cell CD57 expression is distinct from that of CMV and aging
    Sulggi A Lee
    Departments of Medicine, Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 9:e89444. 2014
    ..Whether chronic HIV infection causes similar effects is currently unclear...
  15. pmc HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control
    Brinda Emu
    Positive Health Program, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California, USA
    J Virol 82:5398-407. 2008
    ..Defining mechanisms for virus control in "non-T-cell controllers" might lead to insights into preventing HIV transmission or preventing virus replication...
  16. ncbi request reprint Programmed death-1 expression on CD4⁺ and CD8⁺ T cells in treated and untreated HIV disease
    Leslie R Cockerham
    aHIV AIDS Division, San Francisco General Hospital bDivision of Experimental Medicine cDepartment Epidemiology and Biostatistics, UCSF, San Francisco, California dVaccine and Gene Therapy Institute of Florida, Port St Lucie, Florida, USA
    AIDS 28:1749-58. 2014
    ..However, the impact of HIV infection and antiretroviral treatment (ART) on the expression of PD-1 on T cells is still poorly defined...
  17. ncbi request reprint Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen
    Hiroyu Hatano
    University of California San Francisco, San Francisco, CA, USA
    Clin Infect Dis 43:1329-36. 2006
    ..The major risk of this approach is ongoing viral evolution and the loss of future drug options...
  18. pmc Novel application of Locked Nucleic Acid chemistry for a Taqman assay for measuring diverse human immunodeficiency virus type 1 subtypes
    Peilin Li
    University of California, San Francisco UCSF, Department of Medicine, San Francisco, CA 94121, USA
    J Virol Methods 170:115-20. 2010
    ..765, p<0.0001). This approach to Taqman probe design should be explored further for use in diagnosis and monitoring of HIV in resource-limited settings, especially where several subtypes co-circulate...
  19. pmc Drug resistant HIV
    Hiroyu Hatano
    BMJ 334:1124-5. 2007
  20. ncbi request reprint Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase
    Zixin Hu
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, and Division of AIDS, Harvard Medical School, Boston, MA, USA
    J Acquir Immune Defic Syndr 45:494-500. 2007
    ..These results show that Delta70 enhances resistance to certain purine and pyrimidine analogues and contributes to multinucleoside resistance in the appropriate viral genetic background...
  21. pmc Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1
    Zixin Hu
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, 65 Landsdowne Street, Cambridge, MA 02139, USA
    J Virol 80:7020-7. 2006
    ..These results help explain why T215Y but not T215F usually emerges as the first major TAM, as well as the clustering of L210W with TAM-1 mutations and T215F with TAM-2 mutations...

Research Grants2

  1. Virologic and host factors contributing to HIV control in elite controllers
    Hiroyu Hatano; Fiscal Year: 2007
    This is an application for a K23 award for Dr. Hiroyu Hatano, a fellow in adult infectious diseases at the University of California, San Francisco who is establishing herself as a young investigator in patient-oriented translational ..